Patents Assigned to Neurochem, Inc.
-
Publication number: 20080038192Abstract: Described are methods of assessing whether a subject has or is at risk of having multiple organ amyloidosis (MOA) The method includes detecting a diagnostically predictive collection of biomarkers of multiple organ amyloidosis, wherein the detection of a diagnostically predictive collection of biomarkers indicates the subject has or is at risk of having multiple organ amyloidosis Also described are methods of monitoring treatment of subjects with multiple organ amyloidosis and evaluating therapeutic compounds Representative biomarkers for use in the methods may be selected from variant serum amyloid A (SAA) allele, elevated SAA level, elevated C-reactive protein (CRP) level, depressed glycosammoglycan (GAG) level, elevated interleukin-18 (IL-18) level, elevated macrophage-colony stimulating factor (M-CSF) level, elevated hepatocyte growth factor (HGF) level, presence of an antibody against citrullmated vimentm (Sa), presence of a monoclonal immunoglobulin light chain, increased serum albumin, and increased crType: ApplicationFiled: July 18, 2005Publication date: February 14, 2008Applicant: NEUROCHEM INC.Inventor: Francine Gervais
-
Publication number: 20050038117Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid- +related disease.Type: ApplicationFiled: June 18, 2004Publication date: February 17, 2005Applicants: Neurochem (International) Limited, Queen's University at Kingston, Neurochem, Inc.Inventors: Xianqi Kong, Walter Szarek, Francine Gervais
-
Publication number: 20040248876Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 2, 2003Publication date: December 9, 2004Applicant: Queen's University at Kingston and Neurochem, Inc.Inventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20040006092Abstract: The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound.Type: ApplicationFiled: September 3, 2002Publication date: January 8, 2004Applicant: Neurochem, Inc.Inventors: Robert J. Chalifour, Xianqi Kong, Xinfu Wu, Wenshuo Lu
-
Publication number: 20030194375Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: ApplicationFiled: October 15, 2002Publication date: October 16, 2003Applicant: Queen's University at Kingston and Neurochem, Inc.Inventors: Donald F. Weaver, Christopher Y.K. Tan, Stephen T. Kim, Xianqi Kong, Lan Wei, John R. Carran
-
Patent number: 6329356Abstract: Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.Type: GrantFiled: April 8, 1999Date of Patent: December 11, 2001Assignees: Neurochem, Inc., Queen's University At KingstonInventors: Walter A. Szarek, Xianqi Kong
-
Patent number: 6310073Abstract: Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described.Type: GrantFiled: July 27, 1999Date of Patent: October 30, 2001Assignees: Queen's University at Kingston, Neurochem, Inc.Inventors: Robert Kisilevsky, Allan M. Green, Francine Gervais
-
Patent number: 5858326Abstract: In vivo and in vitro methods of increasing amyloid deposition using amyloid-enhancing compounds are described. Methods of forming amyloid fibrils and screening for agents useful in treating amyloidosis are also described. Animals having non-naturally occurring amyloid deposits produced using the amyloid-enhancing compounds even further are described.Type: GrantFiled: June 6, 1995Date of Patent: January 12, 1999Assignees: Neurochem, Inc., Queen's University at KingstonInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver, Paul Fraser, Xianqi Kong